CytoDyn to Hold Webcast to Provide Company Update

Rhea-AI Summary

CytoDyn Inc. (OTCQB: CYDY) announced a webcast for the investment community on March 31, 2022, featuring key executives, including Board Chair Tanya Urbach and CFO Antonio Migliarese. The session aims to update stakeholders on the company's developments concerning leronlimab, a CCR5 antagonist with potential for various therapeutic uses. Participants can submit questions beforehand at ir@cytodyn.com. The event will begin at 5:30 am PT / 8:30 am ET, with a recorded replay available until April 30, 2022.

Positive

• Webcast scheduled for March 31, 2022, to update investors on company developments.
• Key executives participating in the presentation.

Negative

• None.

VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) --  CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Antonio Migliarese, Chief Financial Officer and Interim President, Scott Kelly, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations, will host an investment community webcast to provide an update on developments at the Company on Thursday, March 31, 2022.

Following the update, questions submitted prior to the webcast as directed below will be addressed to the extent appropriate.

Date:	Thursday, March 31, 2022
Time:	5:30 am PT / 8:30 am ET
Access:	https://services.choruscall.com/mediaframe/webcast.html?webcastid=v9IRoWUq
Questions:	Prior to the webcast, questions can be submitted online to ir@cytodyn.com

This is a livestream presentation. Participants are encouraged to login early prior to the start of the event. The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until April 30, 2022.

CONTACTS
Investors:
Cristina De Leon
Office: 360.980.8524
ir@cytodyn.com

Media:
Dan Zacchei / Joe Germani
Sloane & Company
dzacchei@sloanepr.com / jgermani@sloanepr.com

 

FAQ

What is the agenda for the CytoDyn webcast on March 31, 2022?

The agenda includes updates on company developments regarding leronlimab and Q&A with executives.

Who will be presenting during the CytoDyn investment community webcast?

The presenters include Tanya Urbach (Board Chair), Antonio Migliarese (CFO and Interim President), and Scott Kelly (CMO).

How can I submit questions for the CytoDyn webcast?

Questions can be submitted prior to the webcast via email at ir@cytodyn.com.

What time does the CytoDyn webcast start on March 31, 2022?

The webcast starts at 5:30 am PT / 8:30 am ET.

Is a replay available for the CytoDyn webcast, and for how long?

Yes, a replay will be available for 60 minutes after the conclusion of the webcast until April 30, 2022.